Valeritas Holdings, Inc. (NASDAQ:VLRX) – Equities research analysts at Zacks Investment Research lifted their Q2 2017 earnings estimates for shares of Valeritas Holdings in a report released on Tuesday. Zacks Investment Research analyst B. Marckx now anticipates that the company will post earnings per share of ($1.53) for the quarter, up from their prior estimate of ($1.56). Zacks Investment Research also issued estimates for Valeritas Holdings’ Q3 2017 earnings at ($1.53) EPS, Q4 2017 earnings at ($1.48) EPS, FY2017 earnings at ($7.69) EPS, FY2018 earnings at ($6.09) EPS, FY2019 earnings at ($3.49) EPS and FY2020 earnings at ($2.86) EPS.
Several other research analysts have also recently commented on the stock. B. Riley restated a “buy” rating and set a $10.00 target price on shares of Valeritas Holdings in a report on Wednesday, May 17th. ValuEngine cut shares of Valeritas Holdings from a “sell” rating to a “strong sell” rating in a report on Thursday, May 11th. Finally, Cowen and Company began coverage on shares of Valeritas Holdings in a report on Monday, April 17th. They set an “outperform” rating for the company.
COPYRIGHT VIOLATION NOTICE: “Valeritas Holdings, Inc. (VLRX) Forecasted to Earn Q2 2017 Earnings of ($1.53) Per Share” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://sportsperspectives.com/2017/06/18/valeritas-holdings-inc-vlrx-forecasted-to-earn-q2-2017-earnings-of-1-53-per-share-updated-updated.html.
Valeritas Holdings (NASDAQ:VLRX) opened at 5.00 on Friday. The stock’s 50 day moving average is $6.05 and its 200-day moving average is $24.13. Valeritas Holdings has a 12-month low of $4.51 and a 12-month high of $52.00. The company’s market cap is $8.20 million.
Valeritas Holdings (NASDAQ:VLRX) last released its quarterly earnings results on Friday, May 12th. The company reported ($6.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.72) by $4.20. The firm had revenue of $4.61 million for the quarter, compared to analyst estimates of $4.64 million.
An institutional investor recently bought a new position in Valeritas Holdings stock. HighTower Advisors LLC bought a new stake in Valeritas Holdings, Inc. (NASDAQ:VLRX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 27,400 shares of the company’s stock, valued at approximately $195,000. HighTower Advisors LLC owned 1.67% of Valeritas Holdings as of its most recent filing with the SEC.
In other Valeritas Holdings news, major shareholder Capital Royalty L.P. bought 4,000,000 shares of Valeritas Holdings stock in a transaction that occurred on Tuesday, March 28th. The stock was acquired at an average price of $10.00 per share, for a total transaction of $40,000,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John Edward Timberlake bought 5,000 shares of Valeritas Holdings stock in a transaction that occurred on Wednesday, May 17th. The shares were acquired at an average price of $5.14 per share, with a total value of $25,700.00. Following the acquisition, the insider now directly owns 23,037 shares of the company’s stock, valued at approximately $118,410.18. The disclosure for this purchase can be found here. Insiders have purchased 4,011,900 shares of company stock valued at $40,081,855 in the last 90 days.
Valeritas Holdings Company Profile
Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.
Receive News & Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.